App-Quantinova.ai

The NEDD8 Activating Enzyme Inhibitor Pevonedistat Induces ER Stress/UPR-Mediated Cell Death and Rebalances Homeostasis of Pro- and Anti-Apoptotic Proteins in Favor of Cell Death in Acute Lymphoblastic Leukemia Cells

Gilles M. Leclerc - American Society of Hematology (ASH) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Dexamethasone

The JAK Inhibitor Ruxolitinib Is Effective in Treating T Cell Acute Lymphoblastic Leukemia with Gain of Function Mutations in IL-7R Alpha

Emilee Senkevitch - American Society of Hematology (ASH) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Ruxolitinib phosphate

Post-Remission Treatment with Chemotherapy or Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT) of High-Risk (HR) Philadelphia Chromosome-Negative (Ph-neg) Adult Acute Lymphoblastic Leukemia (ALL) According to Minimal Residual Disease (MRD). Preliminary Results of the Pethema ALL-HR-11 Trial

Josep-Maria Ribera - American Society of Hematology (ASH) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

PEG-asparaginase

Clinical Activity and Persistence of Anti-CD22 Chimeric Antigen Receptor in Children and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL)

Terry J. Fry - American Society of Hematology (ASH) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Cyclophosphamide

Genetics Directing Therapy in Acute Lymphocytic Leukemia: Identifying Risk, Defining Targets

Andrea Biondi - American Society of Hematology (ASH) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Methadone hydrochloride

Epigenetics Directing Therapy in Acute Lymphocytic Leukemia: Emerging Roles and New Therapies

Kathrin M Bernt - American Society of Hematology (ASH) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Decitabine

Disease Response Guiding Therapy in Acute Lymphocytic Leukemia: Pivotal Role of Minimal Residual Disease

Michael A. Pulsipher - American Society of Hematology (ASH) , 2015

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Acute lymphoblastic leukemia

N/A

CNOT1 Microrna Single Nucleotide Polymorphism (SNP) Determines the Occurrence of Methotrexate Related Mucositis in Pediatric Acute Lymphoblastic Leukemia

Natanja Oosterom - American Society of Hematology (ASH) , 2015

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Acute lymphoblastic leukemia

Methotrexate

Aberrant Expression of the Stem Cell microRNA-126 Induces B Cell Malignancy

Silvia Nucera - American Society of Gene & Cell Therapy (ASGCT) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Tetracycline

Depletion of High-Content CD14+ Cells from Apheresis Products is Critical for the Successful Transduction and Expansion of CAR T Cells During Large-Scale cGMP Manufacturing

Xiuyan Wang - American Society of Gene & Cell Therapy (ASGCT) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

N/A

CD19-Targeted CAR T Cells Armored To Secrete IL-12 Demonstrate Superior Efficacy Against B Cell Acute Lymphoblastic Leukemia and Resist Treg Immunosuppression

Peter S. Chang - American Society of Gene & Cell Therapy (ASGCT) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Interleukin

MVhGCSF Is Therapeutic In-Vivo B Cell Malignancies With Neutrophils (PMNs) Playing Different Roles

A. Dey - American Society of Gene & Cell Therapy (ASGCT) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Filgrastim

Variation among follow-up survivorship guidelines for adolescent and young adults (AYA).

Erin Marie Barthel - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

N/A

Functional consequence of cognitive impairment in survivors of childhood acute lymphoblastic leukemia (ALL): The role of cancer symptoms as mediators.

I-Chan Huang - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

N/A

Second neoplasms in survivors of childhood acute lymphoblastic leukemia treated with both chemotherapy and radiotherapy.

Wen Shen Looi - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

N/A

Hypopituitarism in cancer survivors

Eva Marie Erfurth - European Congress of Endocrinology (ECE) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

N/A

High metabolic risk is associated with small hypothalamic volume in acute lymphoblastic leukemia survivors 34 years after cranial radiotherapy

Sanaz Gabery - European Congress of Endocrinology (ECE) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

ghrelin

Other malignancies accompanying differentiated thyroid cancer in Turkish Cypriots: a single-centre study

Umut Mousa - European Congress of Endocrinology (ECE) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Methadone hydrochloride

From T-cell Engineering to CAR therapy: Progress and Prospects

Michel Sadelain - American Society of Hematology (ASH) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

IL-15

Sophia Morel - Digestive Disease Week (DDW) , 2016

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Acute lymphoblastic leukemia

N/A

Filters

2187 Abstracts